

BIOSANTE PHARMACEUTICALS INC

Form S-8

October 03, 2003

[QuickLinks](#) -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on October 3, 2003

Registration No. 333-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

58-2301143

(I.R.S. Employer
Identification No.)

111 Barclay Boulevard, Suite 280

Lincolnshire, Illinois

(Address of Principal Executive Offices)

60069

(Zip Code)

BIOSANTE PHARMACEUTICALS, INC. AMENDED AND RESTATED 1998 STOCK PLAN

(Full title of the plan)

Phillip B. Donenberg

Chief Financial Officer

BioSante Pharmaceuticals, Inc.

111 Barclay Boulevard, Suite 280

Lincolnshire, IL 60069

(Name, address and telephone number,
including area code, of agent for service)

(847) 478-0500

(Telephone number, including area code, of agent for service)

Amy E. Culbert, Esq.

Oppenheimer Wolff & Donnelly LLP

45 South Seventh Street, Suite 3300

Minneapolis, Minnesota 55402

(612) 607-7287

Approximate date of commencement of proposed sale to the public:

Immediately upon the filing of this registration statement

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Amount to be registered(1)	Proposed maximum offering price per share(2)	Proposed maximum aggregate offering price	Amount of registration fee(2)
Common Stock, par value \$0.0001 per share	1,000,000	\$3.13	\$3,130,000	\$253.22

- (1) Represents the increase in the total number of shares reserved for issuance under the registrant's Amended and Restated 1998 Stock Plan. An aggregate of 1,000,000 shares has been previously registered under registration statements on Form S-8 (File Nos. 333-53384 and 333-100238) In addition, pursuant to Rule 416 under the Securities Act of 1933, this registration statement includes an indeterminate number of additional shares that may be offered and sold as a result of anti-dilution provisions described in the registrant's Amended and Restated 1998 Stock Plan.
- (2) Estimated solely for the purpose of calculating the amount of the registration fee and calculated pursuant to Rule 457(h) under the Securities Act as follows: (i) with respect to stock options to purchase shares previously granted under the Amended and Restated 1998 Stock Plan, on the basis of the weighted average exercise price of these stock options, and (ii) with respect to stock options and other awards to be granted under the plan based on the average between the high and low prices of the registrant's common stock on October 1, 2003 on the American Stock Exchange.

**STATEMENT UNDER GENERAL INSTRUCTION E
REGISTRATION OF ADDITIONAL SECURITIES**

The registrant, BioSante Pharmaceuticals, Inc., previously filed registration statements on Form S-8 with the Securities and Exchange Commission (SEC File Nos. 333-53384 and 333-100238) in connection with the registration of an aggregate of 1,000,000 (as adjusted to reflect a 1-for-10 reverse stock split effected on May 31, 2002) shares of BioSante's common stock to be issued under the BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan. BioSante amended the registration statement (SEC File No. 333-53384) by virtue of a post-effective amendment No. 1 pursuant to Rule 414 under the Securities Act of 1933, as amended, to reflect the reincorporation of BioSante from the State of Wyoming to the State of Delaware.

Pursuant to General Instruction E of Form S-8, this registration statement is filed by BioSante solely to register an additional 1,000,000 shares of common stock reserved for issuance under the BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan. This increase was approved by BioSante's board of directors and stockholders. Pursuant to Instruction E, the contents of BioSante's previously filed registration statements on Form S-8 (SEC File Nos. 333-53384 and 333-100238) and the post-effective amendment No. 1 thereto, including without limitation periodic reports that BioSante filed, or will file, after this registration statement to maintain current information about BioSante, are hereby incorporated by reference into this registration statement pursuant to General Instruction E of Form S-8.

Part II

**INFORMATION REQUIRED
IN THE REGISTRATION STATEMENT**

Item 8. Exhibits.

Exhibit No.	Description
-------------	-------------

Edward C. Rosenow, III, M.D.	Director
/s/ FRED HOLUBOW	
Fred Holubow	Director
/s/ ROSS MANGANO	
Ross Mangano	Director
/s/ ANGELA HO	
Angela Ho	Director
/s/ PETER KJAER	
Peter Kjaer	Director

3

**BIOSANTE PHARMACEUTICALS, INC.
REGISTRATION STATEMENT ON FORM S-8**

INDEX TO EXHIBITS

Exhibit No.	Item	Method of Filing
5.1	Opinion of Oppenheimer Wolff & Donnelly LLP	Filed herewith.
23.1	Consent of Deloitte & Touche LLP	Filed herewith.
23.2	Consent of Oppenheimer Wolff & Donnelly LLP	Included in Exhibit 5.1.
24.1	Power of Attorney	Included on the signature page to this registration statement.

QuickLinks

STATEMENT UNDER GENERAL INSTRUCTION E REGISTRATION OF ADDITIONAL SECURITIES

Part II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

SIGNATURES

POWER OF ATTORNEY

INDEX TO EXHIBITS